**Tables:**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Type 2 diabetic patients with overweight | | | Type 2 diabetic patients with obesity | | |
|  | Total | Subjects received add-on with Dapagliflozin | Subjects received add-on with Empagliflozin | Total | Subjects received add-on with Dapagliflozin | Subjects received add-on with Empagliflozin |
| **Baseline characteristics** | | | | | | |
| n | 30 | 16 | 14 | 30 | 14 | 16 |
| Men (n, %) | 26 (86.7%) | 13 (81.3%) | 13 (92.6%) | 21 (70.0%) | 9 (64.3%) | 12 (75.0%) |
| Women (n, %) | 4 (13.3%) | 3 (18.8%) | 1 (7.1%) | 9 (30.0%) | 5 (35.7%) | 4 (25.0%) |
| Smoking (n, %) | 3 (10%) | 2 (12.5%) | 1 (7.1%) | 5 (16.7%) | 2 (14.3%) | 3 (18.8%) |
| Hypertension (n, %) | 13 (43.3%) | 9 (56.3%) | 4 (28.6%) | 19 (63.3%) | 10 (71.4%) | 9 (56.3%) |
| Hypercholesterolemia (n, %) | 24 (80%) | 14 (87.5%) | 10 (71.4%) | 23 (76.7%) | 11 (78.6%) | 12 (75.0%) |
| **Family history** | | | | | | |
| Diabetes Mellitus (n, %) | 22 (73.3%) | 12 (75.5%) | 10 (71.4%) | 24 (80.0%) | 13 (92.9%) | 11 (68.8%) |
| Hypercholesterolemia (n, %) | 2 (6.7%) | 1 (6.3%) | 1 (7.1%) | 2 (6.7%) | 1 (7.1%) | 1 (6.3%) |
| Hypertension (n, %) | 11 (36.7%) | 6 (37.5%) | 5 (35.7%) | 14 (46.7%) | 7 (50.0%) | 7 (43.8%) |
| **Clinical variables** | | | | | | |
| Weight (kg) | 78.2±8.2 | 78.6±9.8 | 77.7±6.4 | 91.1±9.0 | 88.4±6.9 | 93.4±10.1 |
| BMI (kg/m2) | 27.4±1.3 | 27.4±1.5 | 27.3±1.2 | 32.5±1.3 | 32.5±1.1 | 32.4±1.4 |
| WC (cm) | 96.3±3.7 | 96.2±3.6 | 96.4±4.0 | 100.6±4.3 | 99.52±4.5 | 101.5±4.1 |
| Systolic BP (mm/Hg) | 120.0±8.3 | 120.6±8.5 | 119.3±8.3 | 122.3±8.2 | 126.4±7.7 | 118.8±7.0 |
| Diastolic BP (mm/Hg) | 76.0±6.2 | 76.3±6.2 | 75.7±6.5 | 77.0±5.4 | 78.6±5.3 | 75.6±5.1 |
| Data are expressed as means ± SD, n (%).  BMI: Body mass index, WC: Waist circumference, BP: Blood pressure. | | | | | | |

Table 1: Baseline characteristics of the study subjects